Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib DDI Study in IDH1 Mutation-Positive Malignancies
NCT07486713Phase 4Recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Feb 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of olutasidenib in acute myeloid leukemia (AML), glioma, cholangiocarcinoma (CCA), solid tumor, sponsored by Rigel Pharmaceuticals, Inc.. Started Feb 2026; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)gliomacholangiocarcinoma (CCA)solid tumor
Beyond the preview
Go deeper on NCT07486713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486713.